Journal ArticleDOI
The use of bisphosphonates to treat skeletal complications in solid tumours
Reads0
Chats0
TLDR
In this paper, a review of bisphosphonate-based drugs for the treatment of metastatic bone disease is presented, focusing on their continuing value in BM treatment and their future potential in providing a bone-targeting vehicle for cytotoxic drugs.About:
This article is published in Bone.The article was published on 2021-03-04. It has received 13 citations till now. The article focuses on the topics: Bone metastasis & Bone disease.read more
Citations
More filters
Journal ArticleDOI
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management.
Konstantinos Venetis,Roberto Piciotti,Roberto Piciotti,Elham Sajjadi,Elham Sajjadi,Marco Invernizzi,Stefania Morganti,Stefania Morganti,Carmen Criscitiello,Carmen Criscitiello,Nicola Fusco,Nicola Fusco +11 more
TL;DR: In this paper, the state-of-the-art in the characterization and targeting of bone metastasis in breast cancer is outlined, focusing on the major clinical and translational studies on this clinically relevant topic.
Journal ArticleDOI
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Clara Martori,Lidia Sanchez-Moral,Tony Paul,Juan Carlos Pardo,Albert Font,Vicenç Ruiz de Porras,Maria Rosa Sarrias +6 more
TL;DR: The growing field of macrophage-directed immunotherapies is summarized and how these could be applied in the treatment of mPC are discussed, focusing on their combination with ICIs.
Journal ArticleDOI
A glitch in the matrix: organ-specific matrisomes in metastatic niches
TL;DR: In this paper, the extracellular matrix (ECM) modifications support metastasis in four frequent metastatic sites (the lung, liver, bone, and brain) and discuss ways in which these modifications are shared between metastatic organs as well as features specific to each location.
Journal ArticleDOI
Cross Talk Between Macrophages and Cancer Cells in the Bone Metastatic Environment.
TL;DR: In this paper, the authors summarize the reported functions, interactions, and signaling of macrophages with cancer cells during the metastatic cascade to bone and discuss the potential of targeting this crosstalk to inhibit disease progression.
Journal ArticleDOI
Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis
TL;DR: In this article, the relationship between breast cancer and osteoporosis, the influence of NPY on both diseases, and the recent progress in the research and treatment of these diseases are reviewed.
References
More filters
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
Salvatore L. Ruggiero,Thomas B. Dodson,John Fantasia,Reginald Goodday,Tara Aghaloo,Bhoomi Mehrotra,Felice O'Ryan +6 more
TL;DR: The American Association of Oral and Maxillofacial Surgeons (AAOMS) developed guidelines for medication-related osteonecrosis of the jaw (MRONJ) in 2007 and 2009 as mentioned in this paper.
Journal ArticleDOI
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
TL;DR: Improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.
Journal ArticleDOI
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Pekka Saikku,Pekka Saikku,Kimmo Mattila,Kimmo Mattila,Markku S. Nieminen,Markku S. Nieminen,Jussi K. Huttunen,Jussi K. Huttunen,Maija Leinonen,Maija Leinonen,M. R. Ekman,M. R. Ekman,P H Mäkelä,P H Mäkelä,Ville Valtonen,Ville Valtonen +15 more
TL;DR: Investigation for antibodies to a novel type of Chlamydia sp, TWAR, and to chlamydial lipopolysaccharide (LPS) group antigen found they could be a factor in the pathogenesis of cardiovascular diseases.
Journal ArticleDOI
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,H. Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl +13 more
TL;DR: Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad,Donald M. Gleason,Robin Murray,Simon Tchekmedyian,Peter Venner,Louis Lacombe,Joseph L. Chin,Jeferson J. Vinholes,J. Allen Goas,Bee Chen +9 more
TL;DR: Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases and urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic Acid at either dose.